A Preoperative Risk Stratification Approach Using the Focal Risk Group (FRG) in Patients Undergoing Focal Therapy for Localized Prostate Cancer [0.03%]
局部前列腺癌患者行局灶治疗前的风险分层方法——焦风险组(FRG)的建立及验证
Umberto Anceschi,Salvatore Basile,Riccardo Mastroianni et al.
Umberto Anceschi et al.
Introduction: Focal therapy is increasingly used for localized prostate cancer, but preoperative risk stratification remains poorly defined. We developed a Focal Risk Group (FRG), a simple clinically informed classificati...
Uncommon Histological Variants are Associated With Early Biochemical Recurrence After Robot-Assisted Radical Prostatectomy: A Retrospective Study With Exploratory Analysis of Postoperative PSA Outcomes [0.03%]
不常见的组织学变异与机器人辅助根治性前列腺切除术后的早期生化复发相关：术后PSA结果的探索性分析的回顾性研究
Peimin Zhou,Xu Chen,Meng Zhang et al.
Peimin Zhou et al.
Introduction: To evaluate the impact of uncommon histological (UH) variants on oncological outcomes after robot-assisted radical prostatectomy (RARP) in localized prostate cancer. ...
Exploration of the Challenges in the Management of Prostate Cancer in East Africa [0.03%]
东非前列腺癌管理挑战探索
Ismahil Adekunle Adeniyi,Umar Uthman Shehu,Emmanuel Orire Ikuomola et al.
Ismahil Adekunle Adeniyi et al.
Prostate cancer is an increasingly significant public health challenge in East Africa, characterized by a high proportion of cases diagnosed at advanced or metastatic stages and correspondingly elevated mortality rates compared with high-in...
Circulating Tumor DNA as a Novel Indicator of Teratoma in Nonseminomatous Germ Cell Tumor [0.03%]
循环肿瘤DNA可作为非精原细胞瘤性生殖细胞肿瘤中判断畸胎瘤的新标志物
Willian Ito,Nicholas Bingham,John T Lafin et al.
Willian Ito et al.
Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer Outside of Randomized Controlled Trials: A Systematic Review and Meta-Analysis of Prognostic Factors in Real-World Analyses [0.03%]
非随机对照试验中雄激素受体通路抑制剂治疗转移性激素敏感性前列腺癌的预后因素：真实世界分析的系统评价和meta分析
Keiichiro Miyajima,Takafumi Yanagisawa,Marcin Miszczyk et al.
Keiichiro Miyajima et al.
We aimed to analyze prognostic factors for overall survival (OS) and progression-free survival (PFS) in real-world patients treated with androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPI) for metast...
Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis [0.03%]
基线血液学参数与Lu-177 PSMA放射配体治疗（RLT）前列腺癌患者的预后：一项多中心真实世界分析
Colin P Bergstrom,Cameron Chalker,Joseph Allen et al.
Colin P Bergstrom et al.
Background: Radioligand therapy with lutetium-177-labeled prostate-specific membrane antigen 177Lu-PSMA-617 has demonstrated survival benefits in metastatic castration-resistant prostate cancer (mCRPC), yet prognostic mar...
CT-Measured Psoas Area Predicts Urinary Incontinence Trajectories and Persistence After Robotic Prostatectomy: A 12-Month Analysis Using the 1-Hour Pad Test [0.03%]
基于机器人辅助前列腺切除术的12个月1小时护垫试验尿失禁分析：是否可采用CT测量腰大肌面积预测尿失禁轨迹及持续性？
Akihisa Hasegawa,Kenji Omae,Yuki Harigane et al.
Akihisa Hasegawa et al.
Background: Urinary incontinence (UI) remains an important complication after robot-assisted radical prostatectomy (RARP). While sarcopenia-related markers may help predict persistent UI, existing evidence is inconsistent...
A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer [0.03%]
转移性去势抵抗性前列腺癌患者的全面基因组检测的前瞻性研究
Daniel Shevrin,Mathew Yang,Linda M Sabatini et al.
Daniel Shevrin et al.
Background: In addition to germline, somatic genomic testing is the standard of care in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Although initial testing with tissue is recommended by c...
Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis [0.03%]
前列腺癌的肿瘤突变负荷的全面分析：多公共数据集分析
Tomoya Hatayama,Yohei Sekino,Go Kobayashi et al.
Tomoya Hatayama et al.
Introduction: Tumor mutational burden (TMB) is a clinically relevant biomarker for predicting responsiveness to immune checkpoint inhibitors (ICIs). However, in prostate cancer (PCa), the mechanisms underlying TMB elevati...
Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event Reanalysis [0.03%]
贝扎普利班治疗肾细胞癌中枢神经系统转移与依维莫司相比延缓无进展生存期：LITESPARK-005研究的重建时间依赖性再分析
Motohiro Fujiwara,Soichiro Yoshida,Shugo Yajima et al.
Motohiro Fujiwara et al.
Introduction: In the LITESPARK-005 trial, early crossing of the progression-free survival (PFS) Kaplan-Meier curves suggest nonproportional hazards, potentially obscuring time-dependent treatment effects when summarized b...